MaxCyte, Inc.

At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure™ gene editing risk assessment services enable high-performance cell engineering and rigorous evaluation of editing outcomes, supporting confidence in therapeutic development. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine.

Current securities

1. 10-Q filingAug 13, 2026
2. Results of Operations and Financial Condition · Regulation FD DisclosureAug 12, 2026
3. 4 filingJun 22, 2026
4. Submission of Matters to a Vote of Security HoldersJun 17, 2026
5. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingJun 16, 2026